Last updated on November 2018

Pembrolizumab in Combination With Doxorubicin in Advanced Recurrent or Metastatic Endometrial Cancer


Brief description of study

This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.

Clinical Study Identifier: NCT03276013

Find a site near you

Start Over